Codexis, Inc. (CDXS)
| Market Cap | 255.80M |
| Revenue (ttm) | 70.39M |
| Net Income (ttm) | -43.97M |
| Shares Out | 90.87M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,336,845 |
| Open | 2.620 |
| Previous Close | 2.650 |
| Day's Range | 2.605 - 2.835 |
| 52-Week Range | 0.958 - 3.870 |
| Beta | 2.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About CDXS
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The co... [Read more]
Financial Performance
In 2025, Codexis's revenue was $70.39 million, an increase of 18.61% compared to the previous year's $59.35 million. Losses were -$43.97 million, -32.63% less than in 2024.
Financial StatementsNews
Codexis Earnings Call Transcript: Q4 2025
2025 marked a pivotal year with strong revenue growth, key commercial agreements, and technical milestones in the ECO Synthesis platform. Guidance for 2026 anticipates continued revenue growth, stable margins, and further expansion in RNA medicine manufacturing.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway throu...
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it ha...
Codexis Transcript: TD Cowen 46th Annual Health Care Conference
The company is shifting focus from legacy enzyme supply to RNA medicine manufacturing, leveraging its ECO Synthesis platform to address scalability and quality challenges in the growing RNA therapeutics market. Strategic partnerships, new facility investments, and a land-and-expand commercial approach position it for significant growth by 2030.
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...
Codexis Achieves ISO 9001:2015 Certification
REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today th...
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LG...
Codexis Announces Signing of Lease for GMP Manufacturing Facility
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis Earnings Call Transcript: Q3 2025
Signed a major Merck agreement, fueling a strategic shift to oligonucleotide manufacturing and Eco-synthesis. Q3 2025 revenue declined year-over-year, but gross margin improved and cash runway now extends through 2027. Leadership transition and new partnerships support growth.
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
REDWOOD CITY, Calif. , Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avec...
Codexis to Report Third Quarter 2025 Financial Results on November 6
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis Transcript: Cantor Global Healthcare Conference 2025
Demand for siRNA therapeutics is rapidly increasing, outpacing the capacity of traditional chemical synthesis. Enzymatic manufacturing offers scalable, cost-effective solutions, with recent technical milestones and strong customer engagement driving growth. The company is well-funded and focused on building a robust pipeline and long-term partnerships.
Codexis to Participate in Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue nearly double year-over-year, gross margin rise to 72%, and net loss halved. Strong demand for the ECO Synthesis platform is driving capacity expansion, with over 30 customer engagements and new contracts fueling growth.
Codexis Reports Second Quarter 2025 Financial Results
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $2...
Codexis to Report Second Quarter 2025 Financial Results on August 13
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis Transcript: Jefferies Global Healthcare Conference 2025
ECO Synthesis platform has rapidly advanced to commercial adoption, with strong industry demand, a growing customer base, and strategic partnerships. Plans include scaling production, onshoring supply chains, and leveraging AI for process optimization, with revenue growth and positive cash flow targeted by end of 2026.
Codexis Transcript: Status Update
siRNA manufacturing is rapidly shifting toward enzymatic synthesis, with the ECO Synthesis platform gaining strong industry validation and customer traction. Technical advances, including machine learning tools and stereochemistry control, are driving adoption, and the platform is on track for full lab capacity and new partnerships.
Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Codexis to Participate in Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced th...
Codexis Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined year-over-year due to prior one-time items, but gross margin improved and 2025 guidance is reiterated. ECO Synthesis and RNA ligase businesses are gaining traction, with a strong cash position supporting growth and a projected ramp in the second half of the year.
Codexis Reports First Quarter 2025 Financial Results
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming ...
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Codexis to Report First Quarter 2025 Financial Results on May 14
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Codexis Announces Byron Dorgan to Retire from Board of Directors
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...